Laura Rita Rega

Dr. Laura Rita Rega

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Kidney International
Verified
Journal Article
Closed access
LRLaura Rita Rega
Laura Rita Rega
EPElena Polishchuk
Elena Polishchuk
SMSandro Montefusco
Sandro Montefusco
GNGennaro Napolitano
Gennaro Napolitano
GTGIULIA TOZZI
GIULIA TOZZI
FEFrancesco Emma
Francesco Emma

5 June 2020 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
ELEster De Leo
Ester De Leo
Mohamed A. ElmonemMohamed A. Elmonem
Mohamed A. Elmonem
SBSante Princiero Berlingerio
Sante Princiero Berlingerio
MBMarine Berquez
Marine Berquez
BFBeatrice Paola Festa
Beatrice Paola Festa
LRLaura Rita Rega
Laura Rita Rega
Significance Statement: Nephropathic cystinosis, the most severe form of the lysosomal storage disease cystinosis, presents as renal Fanconi syndrome. Defective cystine transport leads to intralysosomal accumulation and crystallization of cystine. The only treatment for cystinosis, cysteamine, does not correct the Fanconi syndrome or prevent progression to ESKD, suggesting involvement of pathways unrelated to lysosomal cystine accumulation. The authors used high-throughput screening to identify molecules that reduce accumulation of the autophagy substrate p62/SQSTM1 in cystinotic proximal tubular epithelial cells and restore normal autophagy. Studies in cells derived from patients with, or mouse models of, cystinosis and in cystinotic zebrafish indicate that luteolin corrects aspects of the cystinotic phenotype that are linked to renal Fanconi syndrome. These findings provide new perspectives for the treatment of nephropathic cystinosis and other renal lysosomal storage diseases. Background: Mutations in the gene that encodes the lysosomal cystine transporter cystinosin cause the lysosomal storage disease cystinosis. Defective cystine transport leads to intralysosomal accumulation and crystallization of cystine. The most severe phenotype, nephropathic cystinosis, manifests during the first months of life, as renal Fanconi syndrome. The cystine-depleting agent cysteamine significantly delays symptoms, but it cannot prevent progression to ESKD and does not treat Fanconi syndrome. This suggests the involvement of pathways in nephropathic cystinosis that are unrelated to lysosomal cystine accumulation. Recent data indicate that one such potential pathway, lysosome-mediated degradation of autophagy cargoes, is compromised in cystinosis. Methods: To identify drugs that reduce levels of the autophagy-related protein p62/SQSTM1 in cystinotic proximal tubular epithelial cells, we performed a high-throughput screening on the basis of an in-cell ELISA assay. We then tested a promising candidate in cells derived from patients with, and mouse models of, cystinosis, and in preclinical studies in cystinotic zebrafish. Results: Of 46 compounds identified as reducing p62/SQSTM1 levels in cystinotic cells, we selected luteolin on the basis of its efficacy, safety profile, and similarity to genistein, which we previously showed to ameliorate other lysosomal abnormalities of cystinotic cells. Our data show that luteolin improves the autophagy–lysosome degradative pathway, is a powerful antioxidant, and has antiapoptotic properties. Moreover, luteolin stimulates endocytosis and improves the expression of the endocytic receptor megalin. Conclusions: Our data show that luteolin improves defective pathways of cystinosis and has a good safety profile, and thus has potential as a treatment for nephropathic cystinosis and other renal lysosomal storage diseases.

Verified
Journal Article
Open access
PDF file
FBFrancesco Bellomo
Francesco Bellomo
ELEster De Leo
Ester De Leo
ATAnna Taranta
Anna Taranta
LGLaura Giaquinto
Laura Giaquinto
GGGianna Di Giovamberardino
Gianna Di Giovamberardino
FEFrancesco Emma
Francesco Emma
Diagnosis and cure for rare diseases represent a great challenge for the scientific community who often comes up against the complexity and heterogeneity of clinical picture associated to a high cost and time-consuming drug development processes. Here we show a drug repurposing strategy applied to nephropathic cystinosis, a rare inherited disorder belonging to the lysosomal storage diseases. This approach consists in combining mechanism-based and cell-based screenings, coupled with an affordable computational analysis, which could result very useful to predict therapeutic responses at both molecular and system levels. Then, we identified potential drugs and metabolic pathways relevant for the pathophysiology of nephropathic cystinosis by comparing gene-expression signature of drugs that share common mechanisms of action or that involve similar pathways with the disease gene-expression signature achieved with RNA-seq.

12 July 2024 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
FBFrancesco Bellomo
Francesco Bellomo
SPSara Pugliese
Sara Pugliese
SCSara Cairoli
Sara Cairoli
PKPatrick Krohn
Patrick Krohn
CSCristiano De Stefanis
Cristiano De Stefanis
FEFrancesco Emma
Francesco Emma
Key Points: Ketogenic diet can change the metabolism in the body and helped restore the function of altered pathways in nephropathic cystinosis. Ketogenic diet had significant benefits for preventing kidney damage, even when initiated after the onset of kidney impairment. Ketogenic diet may provide a partial therapeutic alternative in countries where cysteamine therapy is too expensive. Background: Nephropathic cystinosis is a rare inherited lysosomal storage disorder caused by mutations in the CTNS gene that encodes for cystinosin, a lysosomal cystine/H+ symporter. From the standpoint of the kidneys, patients develop early-onset renal Fanconi syndrome and progressive CKD. Current therapy with cysteamine delays but does not prevent kidney failure and has significant side effects that limit adherence and reduce the quality of life of patients. Methods: We have tested biochemically and histologically the effects of ketogenic diet on kidney disease of two animal models of nephropathic cystinosis. Results: When Ctns −/− mice were fed with ketogenic diet from 3 to 12 months of age, we observed significant nearly complete prevention of Fanconi syndrome, including low molecular weight proteinuria, glycosuria, and polyuria. Compared with wild-type animals, BUN at 12 months was higher in cystinotic mice fed with standard diet (P < 0.001), but not with ketogenic diet. At sacrifice, kidneys of knockout mice fed with ketogenic diet appeared macroscopically similar to those of wild-type animals, which was reflected microscopically by a significant reduction of interstitial cell infiltration (CD3 and CD68 positive cells, P < 0.01), of interstitial fibrosis (Masson and α-smooth muscle actin staining, P < 0.001), and of apoptosis (cleaved caspase-3 levels; P < 0.001), and by indirect evidence of restoration of a normal autophagic flux (SQSTM1/p62 and LC3-II expression, P < 0.05). Beneficial effects of ketogenic diet on tubular function were also observed after mice were fed with this ketogenic diet from the age of 6 months to the age of 15 months, after they had developed proximal tubular dysfunction. Although slightly less pronounced, these results were replicated in Ctns −/− rats fed with ketogenic diet from 2 to 8 months of life. Conclusions: These results indicate significant mitigation of the kidney phenotype in cystinotic animals fed with ketogenic diet.

27 October 2022 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ELEster De Leo
Ester De Leo
ATAnna Taranta
Anna Taranta
RRRoberto Raso
Roberto Raso
EPElena Polishchuk
Elena Polishchuk
VDValentina D’oRia
Valentina D’oRia
LRLaura Rita Rega
Laura Rita Rega
Cysteamine is currently the only therapy for nephropathic cystinosis. It significantly improves life expectancy and delays progression to end-stage kidney disease; however, it cannot prevent it. Unfortunately, compliance to therapy is often weak, particularly during adolescence. Therefore, finding better treatments is a priority in the field of cystinosis. Previously, we found that genistein, an isoflavone particularly enriched in soy, can revert part of the cystinotic cellular phenotype that is not sensitive to cysteamine in vitro. To test the effects of genistein in vivo, we fed 2-month-old wild-type and Ctns−/− female mice with either a control diet, a genistein-containing diet or a cysteamine-containing diet for 14 months. Genistein (160 mg/kg/day) did not affect the growth of the mice or hepatic functionality. Compared with untreated mice at 16 months, Ctns−/− mice fed with genistein had lower cystine concentrations in their kidneys, reduced formation of cystine crystals, a smaller number of LAMP1-positive structures and an overall better-preserved parenchymal architecture. Cysteamine (400 mg/kg/day) was efficient in reverting the lysosomal phenotype and in preventing the development of renal lesions. These preclinical data indicate that genistein ameliorates kidney injury resulting from cystinosis with no side effects. Genistein therapy represents a potential treatment to improve the outcome for patients with cystinosis.

8 February 2022 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
PKPatrick Krohn
Patrick Krohn
LRLaura Rita Rega
Laura Rita Rega
MHMarianne Harvent
Marianne Harvent
BFBeatrice Paola Festa
Beatrice Paola Festa
ATAnna Taranta
Anna Taranta
ODOlivier Devuyst
Olivier Devuyst
Recessive mutations in the CTNS gene encoding the lysosomal transporter cystinosin cause cystinosis, a lysosomal storage disease leading to kidney failure and multisystem manifestations. A Ctns knockout mouse model recapitulates features of cystinosis, but the delayed onset of kidney manifestations, phenotype variability and strain effects limit its use for mechanistic and drug development studies. To provide a better model for cystinosis, we generated a Ctns knockout rat model using CRISPR/Cas9 technology. The Ctns−/− rats display progressive cystine accumulation and crystal formation in multiple tissues including kidney, liver and thyroid. They show an early onset and progressive loss of urinary solutes, indicating generalized proximal tubule dysfunction, with development of typical swan-neck lesions, tubulointerstitial fibrosis and kidney failure, and decreased survival. The Ctns−/− rats also present crystals in the cornea, and bone and liver defects, as observed in patients. Mechanistically, the loss of cystinosin induces a phenotype switch associating abnormal proliferation and dedifferentiation, loss of apical receptors and transporters, and defective lysosomal activity and autophagy in the cells. Primary cultures of proximal tubule cells derived from the Ctns−/− rat kidneys confirmed the key changes caused by cystine overload, including reduced endocytic uptake, increased proliferation and defective lysosomal dynamics and autophagy. The novel Ctns−/− rat model and derived proximal tubule cell system provide invaluable tools to investigate the pathogenesis of cystinosis and to accelerate drug discovery.